α‐synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine‐rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain

ABSTRACT Objectives: A recent study showed that Arab‐Berbers GG homozygous at rs2421947(C/G) in the dynamin 3 gene (DNM3) had 12.5 years earlier age at onset of leucine‐rich repeat kinase 2 (LRRK2)‐associated Parkinson's disease (PD) (L2PD). We explored whether this variant modulates the L2PD a...

Full description

Saved in:
Bibliographic Details
Published inMovement disorders Vol. 33; no. 4; pp. 637 - 641
Main Authors Fernández‐Santiago, Rubén, Garrido, Alicia, Infante, Jon, González‐Aramburu, Isabel, Sierra, María, Fernández, Manel, Valldeoriola, Francesc, Muñoz, Esteban, Compta, Yaroslau, Martí, María‐José, Ríos, José, Tolosa, Eduardo, Ezquerra, Mario
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.04.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:ABSTRACT Objectives: A recent study showed that Arab‐Berbers GG homozygous at rs2421947(C/G) in the dynamin 3 gene (DNM3) had 12.5 years earlier age at onset of leucine‐rich repeat kinase 2 (LRRK2)‐associated Parkinson's disease (PD) (L2PD). We explored whether this variant modulates the L2PD age at onset in Spain. Methods: We genotyped rs2421947 in 329 participants (210 L2PD patients, 119 L2PD nonmanifesting p.G2019S carriers), and marker rs356219 (A/G) in the α‐synuclein gene (SNCA). Results: By Kaplan Meier and Cox regression analyses, we did not find an association of the DNM3 polymorphism with L2PD age at onset. However, we found an association of the SNCA marker with up to an 11 years difference in the L2PD median age at onset (58 years for GG carriers vs 69 years for AA). Conclusion: Our results indicate that SNCA rs356219 but not dynamin 3 DNM3 rs2421947 modifies the penetrance of the mutation G2019S in the Spanish population by influencing the L2PD age at onset. These findings suggest that different genetic modifiers may influence the L2PD age at onset in different populations. © 2018 International Parkinson and Movement Disorder Society
Bibliography:Nothing to report.
This work was supported by the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas to the Movement Disorders Unit of the Neurology Service from the Hospital Clínic de Barcelona to E.T., M.‐J.M., R.F.‐S., M.E., F.V., E.M., and Y.C. (Grant PRI‐16‐2017). R.F.‐S. was supported by a Jóvenes Investigadores grant of the Spanish Ministry of Economy and Competitiveness (Grant SAF2015‐73508‐JIN, Agencia Estatal de Investigación/Fondo Europeo de Desarrollo Regional/Unión Europea (AEI/FEDER/UE)), and M.E. by a Miguel Servet contract of the Instituto de Salud Carlos III (ISCIII)/Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS).
Relevant conflicts of interests/financial disclosures
See appendix.
Funding agencies
Rubén Fernández‐Santiago and Alicia Garrido contributed equally to this work. Eduardo Tolosa and Mario Ezquerra are cosenior authors. Members of the Barcelona LRRK2 Study Group are listed in the Acknowledgments.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.27295